Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme

European Heart Journal

Volumn 29, Issue 21, 2008, Pages 2641-2650

  Pocock, Stuart J ^a   McMurray, John J V ^b   Dobson, Joanna ^a   Yusuf, Salim ^c   Granger, Christopher B ^d   Michelson, Eric L ^e   Östergren, Jan ^f   Pfeffer, Marc A ^g   Solomon, Scott D ^g   Anker, Stefan D ^h   Swedberg, Karl B ⁱ  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c HAMILTON HEALTH SCIENCES   (Canada)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e ASTRAZENECA   (United Kingdom)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Chronic heart failure; Clinical trial database; Mortality; Weight loss

Indexed keywords

CANDESARTAN;

ADULT; AGED; ARTICLE; BODY MASS; DYING; EDEMA; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HIGH RISK PATIENT; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; WEIGHT REDUCTION;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BODY MASS INDEX; CHRONIC DISEASE; EPIDEMIOLOGIC METHODS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; STROKE VOLUME; TETRAZOLES; THINNESS; VENTRICULAR DYSFUNCTION, LEFT; WEIGHT LOSS; YOUNG ADULT;

EID: 55749096258     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn420     Document Type: Article

References (34)

1. Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LA, Skali H, Pfeffer MA, Yusuf S, Swedberg K, Michelson EL, Granger CB, McMurray JJ, Solomon SD, CHARM Investigators. Body mass index and prognosis in patients with chronic heart failure - insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007;116:627-636.
2. Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A, Grobbee DE. The prognosis of heart failure in the general population: the Rotterdam Study. Eur Heart J 2001;22:1318-1327.
3. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 2001;38:789-795.
4. Lissin JW, Gauri AJ, Froelicher VF, Ghayoumi A, Myers J, Giacomini J. The prognostic value of body mass index and standard exercise testing in male veterans with congestive heart failure. J Card Fail 2002;8:206- 215.
5. Davos CH, Doehner W, Rauchhaus M, Cicoira M, Francis DP, Coats AJ, Clark AL, Anker SD. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail 2003;9:29-35.
6. Lavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol 2003;91:891-894.
7. Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F, Kosiborod M, Portnay EL, Sokol SI, Bader F, Krumholz HM. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005;165:55-61.
8. Gustafsson F, Kragelund CB, Torp-Pederson C, Seibaek M, Burchardt H, Akkan D, Thune JJ, Køber L, DIAMOND Study Group. Effect of obesity and being overweight on long-term mortality in congestive heart failure: influence of left ventricular systolic function. Eur Heart J 2005;26:58-64.
9. Bozkurt B, Deswal A. Obesity as a prognostic factor in chronic symptomatic heart failure. Am Heart J 2005;150:1233-1236.
10. Cicoira M, Maggione AP, Latini R, Barlera S, Carretta E, Janosi A, Soler Soler J, Anand I, Cohn JN, Val-HeFT Investigators. Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure Trial. Eur J Heart Fail 2007;9:397-402.
11. Habbu A, Nasser NM, Dokainish H. The obesity paradox: fact or fiction? Am J Cardiol 2006;98:944-948.
12. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050-1053.
13. Anker SD, Negassa A, Coats A J, Afzal R, Poole-Wilson PA, Cohn JN, Yusuf S. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077-1083.
14. Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, Olofsson B, Ostergren J, Yusuf S. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. CHARM Programme Investigators. J Card Fail 1999;5:276-282.
15. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, CHARM Investigators Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-766.
16. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006;27:65-75.
17. Altman DG, de Stavola BL. Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med 1994;13:301-341.
18. Altman DG, Lausen B, Sauerbrei, Schumacher M. Dangers of using 'optimal' cut-offs in the evaluation of prognostic factors. J Nat Cancer Inst 1994;86:829-835.
19. Knudtson MD, Klein BEK, Klein R, Shankar A. Associations with weight loss and subsequent mortality risk. Ann Epidemiol 2005;15:483-491.
20. Sorensen TI. Weight loss causes increased mortality: pros. Obes Rev 2003;4:3-7.
21. Yang D, Fontaine KR, Wang C, Allison DB. Weight loss causes increased mortality: cons. Obes Rev 2003;4:9-16.
22. Kalantar-Zadeh K, Horwich TB, Oreopoulos A, Kovesdy CP, Younessi H, Anker SD, Morley JE. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care 2007;10:433-442.
23. Kalantar-Zadeh K, Abbott KC, Kronenberg F, Anker SD, Horwich TB, Fonarow GC. Epidemiology of dialysis patients and heart failure patients. Semin Nephrol 2006;26:118-133.
24. Koehler F, Doehner W, Hoernig S, Witt C, Anker SD, John M. Anorexia in chronic obstructive pulmonary disease-association to cachexia and hormonal derangement. Int J Cardiol 2007;119:83-89.
25. Anker SD, Ponikowski PP, Clark AL, Leyva F, Kemp M, Rauchhaus M, Hooper J, Poole-Wilson PA, Coats AJS. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999;20:683-693.
26. von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res 2007;73:298-309.
27. von Haehling S, Jankowska EA, Anker SD. Tumour necrosis factor-alpha and the failing heart - pathophysiology and therapeutic implications. Basic Res Cardiol 2004;99:18-28.
28. Niebauer J, Pflaum C-D, Clark AL, Strasburger CJ, Hooper J, Poole-Wilson PA, Coats AJS, Anker SD. Deficient insulin-like growth factor-1 in chronic heart failure predicts altered body composition, cytokine and neurohormonal activation. J Am Coll Cardiol 1998;32:393-397.
29. Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A, Remme W, Moullet C, Swedberg K, Cleland JG, Poole-Wilson PA. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 2006;27:1440-1446.
30. Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE, Delafontaine P. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology 2001;142:1489-1496.
31. Strassburg S, Springer J, Anker SD. Muscle wasting in cardiac cachexia. Int J Biochem Cell Biol 2005;37:1938-1947.
32. Anker SD, Steinborn W, Strassburg S. Cardiac cachexia. Ann Med 2004;36:518-529.
33. Delafontaine P, Akao M. Angiotensin II as candidate of cardiac cachexia. Curr Opin Clin Nutr Metab Care 2006;9:220-224.
34. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Banker SD. Cachexia: a new definition. Clin Nutr 2008; (in press). doi:10.1016/j.clnu.2008.06.013. Published online ahead of print August 21, 2008.